Modeling the Economic Burden of Disease during Dry Eye Syndrome Prophylaxis in Patients after Cataract Phacoemulsification
A. V. Trubilin,
V. N. Trubilin,
E. G. Poluninа,
L. Yu. Bezmel’nitsyna,
E. A. Kasparova,
S. I. Arabadzhyan,
A. V. Filonenko https://doi.org/10.18008/1816-5095-2025-3-669-676
Abstract
The evaluation the burden of disease is an important aspect of modern medical science, such studies clearly illustrate the need for preventive measures aimed not only at improving the quality of life of patients, but also at the possibility of saving the state budget. It can become a reason for additional investments in the healthcare system from the state. A comprehensive analysis of the preventive treatment’s impact on dry eye syndrome for preparing patients for cataract phacoemulsification in accordance with the developed algorithm, which involves a differentiated approach based on the severity of dry eye syndrome, allowed us to determine the following indicators. In the absence of preventive treatment for dry eye syndrome (DES). Тhe duration of the disease is extended by an average of 35 %. It means that the patient will receive 38.64 % less money than the minimum level for living in Moscow. At the population level, assuming that only 1/3 (33 %) of 14,000 patients with severe dry eye syndrome complications are employed, i.e., 4,620 persons, the loss of wages amounts to up to 46,200,000 rubles from the patient’s perspective. It has been established that from the government’s point of view, financial expenses for temporary disability payments can reach up to 75,679,800 rubles per year. A course of therapy aimed at preventing the development of severe DYS in the postoperative period in patients with cataract phacoemulsification during their preparation for surgical treatment will reduce the total burden of the disease (direct and indirect costs) by 115,416,000 rubles per year. The obtained data indicate the needs of the ophthalmologists’ attention to the importance of timely diagnosis of DYS at the stage of patient rehabilitation for planned ophthalmic surgery, in particular, for cataract phacoemulsification. It’ll reduce the incidence of severe forms of DES, improve the quality of life of patients, and decrease costs for both the patient and the government.
About the Authors
A. V. Trubilin
Academy of Postgraduate Education of FMBA of Russia
Russian Federation
Russian Federation
Alexander V. Trubilin - PhD, Associate Professor of the of Ophthalmology Department.
Volokolamskoye highway, 91, Moscow, 125371
V. N. Trubilin
Academy of Postgraduate Education of FMBA of Russia
Russian Federation
Russian Federation
Vladimir N. Trubilin - МD, Professor, Head of the of Ophthalmology Department.
Volokolamskoye highway, 91, Moscow, 125371
E. G. Poluninа
Academy of Postgraduate Education of FMBA of Russia
Russian Federation
Russian Federation
Elizabet G. Poluninа - MD, Professor, Professor of the of Ophthalmology Department.
Volokolamskoye highway, 91, Moscow, 125371
L. Yu. Bezmel’nitsyna
Academy of Postgraduate Education Children and Teenagers of FMBA of Russia
Russian Federation
Russian Federation
Lyudmila Yu. Bezmelnitsyna - head of the Day Hospital Department of the Center for Children’s Sports.
Moskvorechye str., 20, Moscow, 115409
E. A. Kasparova
Krasnov Research Institute of Eye Diseases
Russian Federation
Russian Federation
Evgeniya A. Kasparova - PhD, senior research officer.
Rossolimo str., 11A, B, Moscow, 119021
S. I. Arabadzhyan
Samara State Medical University
Russian Federation
Russian Federation
Sergey I. Arabadzhyan - PhD, Associate Professor of the Reproductive Medicine, Clinical Embryology and Genetics Department.
Chapaevskaya str., 89, Samara, 443099
A. V. Filonenko
City Clinical Hospital No. 12
Russian Federation
Russian Federation
Alexandra V. Filonenko - ophthalmic surgeon, head of the Ophthalmology Department.
Pavel Mochalov str., 8, Nizhny Novgorod 603003
References
1. Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, Bloom DE, Wang C. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study. Lancet Glob Health. 2023 Aug;11(8):e1183–e1193. doi: 10.1016/S2214-109X(23)00217-6.
2. Li Y, Du X, Wu Y, Xu X, Chen S, Cao Z, Wang J, Huang Y, Rong S, Zhong VW. Estimates and projections in the economic impacts of fifteen dietary risk factors for two hundred four countries and territories from 2020 to 2050: A health-augmented macroeconomic modeling study. Am J Clin Nutr. 2025 May;121(5):1099–1108. doi: 10.1016/j.ajcnut.2025.03.002.
3. Rochmah TN, Rahmawati IT, Dahlui M, Budiarto W, Bilqis N. Economic Burden of Stroke Disease: A Systematic Review. Int J Environ Res Public Health. 2021 Jul 15;18(14):7552. doi: 10.3390/ijerph18147552.
4. Chen S, Cao Z, Nandi A, Counts N, Jiao L, Prettner K, Kuhn M, Seligman B, Tortorice D, Vigo D, Wang C, Bloom DE. The global macroeconomic burden of Alzheimer’s disease and other dementias: estimates and projections for 152 countries or territories. Lancet Glob Health. 2024 Sep;12(9):e1534–e1543. doi: 10.1016/S2214-109X(24)00264-X.
5. Tay LX, Ong SC, Tay LJ, Ng T, Parumasivam T. Economic Burden of Alzheimer’s Disease: A Systematic Review. Value Health Reg Issues. 2024 Mar;40:1–12. doi: 10.1016/j.vhri.2023.09.008.
6. Tahami Monfared AA, Khachatryan A, Hummel N, Kopiec A, Martinez M, Zhang R, Zhang Q. Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer’s Disease Continuum Using Patient-Caregiver Dyad Surveys. J Alzheimers Dis. 2024;99(1):191–206. doi: 10.3233/JAD-231259.
7. Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. The Humanistic and Economic Burden of Alzheimer’s Disease. Neurol Ther. 2022 Jun;11(2):525–551. doi: 10.1007/s40120-022-00335-x.
8. Stites SD, Karlawish J, Harkins K, Rubright JD, Wolk D. Awareness of Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia Diagnoses Associated With Lower Self-Ratings of Quality of Life in Older Adults. J Gerontol B Psychol Sci Soc Sci. 2017 Oct 1;72(6):974–985. doi: 10.1093/geronb/gbx100.
9. Martins R, Urbich M, Brännvall K, Gianinazzi M, Ching JE, Khoury CP, El-Hayek YH. Modelling the Pan-European Economic Burden of Alzheimer’s Disease. JAR Life. 2022 Nov 15;11:38–46. doi: 10.14283/jarlife.2022.7.
10. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Глобальная распространенность возрастной макулярной дегенерации и прогноз бремени болезней на 2020 и 2040 годы: систематический обзор и метаанализ. Lancet Glob Health. 2014 февр.;2(2):e106–116. doi: 10.1016/S2214-109X(13)70145-1.
11. Jonas JB. Global prevalence of age-related macular degeneration. Lancet Glob Health. 2014 Feb;2(2):e65–66. doi: 10.1016/S2214-109X(13)70163-3.
12. Wang Y, Zhong Y, Zhang L, Wu Q, Tham Y, Rim TH, Kithinji DM, Wu J, Cheng C, Liang H, Yu H, Yang X, Liu L. Global Incidence, Progression, and Risk Factors of Age-Related Macular Degeneration and Projection of Disease Statistics in 30 Years: A Modeling Study. Gerontology. 2022;68(7):721–735. doi: 10.1159/000518822.
13. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013.
14. Barkana Y, Dorairaj S. Re: Tham et al.: Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis (Ophthalmology 2014;121:2081-90). Ophthalmology. 2015 Jul;122(7):e40–41. doi: 10.1016/j.ophtha.2014.11.030.
15. Song P, Wang J, Bucan K, Theodoratou E, Rudan I, Chan KY. National and subnational prevalence and burden of glaucoma in China: A systematic analysis. J Glob Health. 2017 Dec;7(2):020705. doi: 10.7189/jogh.07.020705.
16. Song P, Yu J, Chan KY, Theodoratou E, Rudan I. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. J Glob Health. 2018 Jun;8(1):010803. doi: 10.7189/jogh.08.010803.
17. Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, Tang Y, Lu Y, Wong IY, Ting DSW, Tan GSW, Jonas JB, Sabanayagam C, Wong TY, Cheng CY. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology. 2021 Nov;128(11):1580–1591. doi: 10.1016/j.ophtha.2021.04.027.
18. Al-Namaeh M. Common causes of visual impairment in the elderly. Med Hypothesis Discov Innov Ophthalmol. 2022 Feb 24;10(4):191–200. doi: 10.51329/mehdiophthal1438.
19. Song P, Wang H, Theodoratou E, Chan KY, Rudan I. The national and subnational prevalence of cataract and cataract blindness in China: a systematic review and meta-analysis. J Glob Health. 2018 Jun;8(1):010804. doi: 10.7189/jogh.08.010804.
20. Villani E, Catania AG, Luccarelli SV, Magnani F, Martone G, Zanzottera E, Lagali N. Dry eye and cataract surgery: Narrative review and recommendations for management. Eur J Ophthalmol. 2023 May 7:11206721231174060. doi: 10.1177/11206721231174060.
21. Sakhnov SN, Yanchenko SV, Malyshev AV, Karapetov GY, Katkhanov TG, Petrosyan LM, Baskakov OA, Dobronosova YA, Kolomiets GL, Lepa TI, Lysov EE, Tseeva AR. Therapeutic hygiene of eyelids in dry eye disease prior to cataract phacoemulsification. Vestn Oftalmol. 2023;139(1):46–54 (In Russ.). doi: 10.17116/oftalma202313901146.
22. Fan L, He T, Shi J, Ke X, Lu X. Effects of Recombinant Human Epidermal Growth Factor Eye Drops Combined with Phacoemulsification on Short- and Long-Term Visual Acuity Recovery and Related Dry Eye Complications in Patients with Senile Cataract. Comput Math Methods Med. 2022 Jun 28;2022:1041558. doi: 10.1155/2022/1041558. Retraction in: Comput Math Methods Med. 2023 Dec 6;2023:9760932. doi: 10.1155/2023/9760932.
23. Chen WT, Chen YY, Hung MC. Dry Eye Following Femtosecond Laser-Assisted Cataract Surgery: A Meta-Analysis. J Clin Med. 2022 Oct 22;11(21):6228. doi: 10.3390/jcm11216228.
24. Lu Q, Lu Y, Zhu X. Dry Eye and Phacoemulsification Cataract Surgery: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021 Jul 8;8:649030. doi: 10.3389/fmed.2021.649030.
25. Trubilin АV, Trubilin VN, Poluninа EG, Kasparova EA, Andzhelova DV, Mirzabekova KA, Evstigneeva YuV, Chinenova KV, Leshenko IA. New Comprehensive Clinical Classification of the Dry Eye Syndrome Severity 2024. Part 2. Treatment Algorithm — the Opinion of Ophthalmologists. Ophthalmology in Russia. 2025;22(1):74–83 (In Russ.). doi: 10.18008/1816-5095-2025-1-74-83.
26. Trubilin AV, Trubilin VN, Poluninа EG, Kasparova EA. New Comprehensive Clinical Classification of Dry Eye Syndrome Severity 2024. Part 1. Ophthalmology in Russia. 2024;21(4):709–715 (In Russ.). doi: 10.18008/1816-5095-2024-4-709-715.
27. Clinical recommendations of the Ministry of Health of the Russian Federation and the Federal State Budgetary Institution “Helmholtz National Medical Research Center of Clinical Hospitals” from 2024. http://avo-portal.ru/doc/fhr/re-discussion/item/467-katarakta-starcheskaya
Review
For citations:
Trubilin A.V., Trubilin V.N., Poluninа E.G., Bezmel’nitsyna L.Yu., Kasparova E.A., Arabadzhyan S.I., Filonenko A.V. Modeling the Economic Burden of Disease during Dry Eye Syndrome Prophylaxis in Patients after Cataract Phacoemulsification. Ophthalmology in Russia. 2025;22(3):669-676. (In Russ.) https://doi.org/10.18008/1816-5095-2025-3-669-676
Views:
11
Email this article 